Embarrassed to say, but after 3 years of being safe, I finally got COVID for the first time. I honestly thought we were past this (society seems to have moved on) but clearly I was wrong.

Posting to bring awareness that we still need to #MaskUp at conferences #ASCO23 ASTRO

At #ASCO23 , PF-07257876 unexpectedly exhibited high engagement with #CD47 and #PDL1 in peripheral blood, indicating it didn't function according to its original design specifications. The findings also raised concerns about its efficacy and safety.

🚨Excited to announce our FIRST IMG Oncologists Town Hall!!

Our 1st event after IMG CoP session at #ASCO23 ✌🏻

We will be talking about future steps and introducing our subcommittees!
Everyone interested in volunteering/learning more are invited to join:
tinyurl.com/5bavjva2

Seems relevant to resurface Dr Andrew Ko’s observation at #asco23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX ‼️

After a long weekend & this Tue, the #HealthcareUnfiltered returns with GU Power Hour hosting the ⁦Rana McKay⁩ & ⁦Neeraj Agarwal, MD, FASCO⁩ to update us all on groundbreaking data from ⁦ASCO⁩ #ASCO23 .

Get the details & data here.

A short clip 👇👇👇 W more to come.

Time to Prep for #ASCO24 ! #lcsm #MedTwitter #ai
👉Here's a great example of what is possible now with new advances in Artificial Intelligence and KOL Pulse AI.
🤖Try out this new experimental KOL Pulse AI Chatbot for the ADAURA Trial, the #ASCO23 plenary.
👨‍⚕️👩🏽‍⚕️The Chatbot uses

Dr. Javier Cortes MD PhD presented the #PHERGain 3-year disease-free survival results at #ASCO23 and, following The Lancet publication, emphasized the achievements attained in this study.

Learn more about the study: medsir.org/post/revolutio…

#MEDSIRtheLancet #OncologyResearch

GU Cancer Highlights from #ASCO23 w/Toni Choueiri, MD

- #TALAPRO2
- #CLEAR
- #CONTACT03
- #THOR

Full Discussion:
- oncbrothers.com/gu-asco2023/
- Podcast tinyurl.com/OncBro

#gusm ASCO #OncTwitter #MedTwitter Hem-Onc Fellows Network Targeted Oncology #MedEd OncoAlert IMG Oncologists #OncEd

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial | Journal of Clinical Oncology

Simple solutions to seemingly complex problems👇

Journal of Clinical Oncology #ASCO23 ascopubs.org/doi/10.1200/JC…

Delighted to share our ASCO Education Book article: the High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions

We review the factors leading to the extremely high cost of CAR T-cells & propose potential solutions

🧵👇

ascopubs.org/doi/abs/10.120…
#ASCO23

As I shared at #ASCO23 , the Inflation Reduction Act poses an alarming threat to #cancer R&D, with biopharmaceutical companies already being forced to rethink investment. Ultimately, patients may lose out with fewer treatment options. Read more: phrma.org/blog/new-repor…

I had a blast hosting Rana McKay of UC San Diego Health & Neeraj Agarwal, MD, FASCO of Huntsman Cancer Institute on my #HealthcareUnfiltered Podcast discussing all things GU from the last ASCO #ASCO23 meeting and how some data might have immediate clinical applications.

Watch these two gurus on the show.

#MOGA23 better than #ASCO23 ? Medical Oncology Group of Australia ASCO Bishal Gyawali Matteo Lambertini, MD PhD

w/Jonathan Friedberg we🗣️2 practice changing📑

- #POLARIX : #Pola 1L DLBCL
- SWOG Cancer Research Network #S1826 : Nivo cHL

Full discussion:
- oncbrothers.com/polarix-swogs1…
- targetedonc.com/pivotal-practi…
- “Oncology Brothers” podcast

#lymsm #HemeTwitter #MedTwitter Targeted Oncology #ASCO23 Journal of Clinical Oncology Wilmot Cancer Institute

Happy #FlashbackFriday ! American Cancer Society (ACS) spoke with CA Editor Don S. Dizon MD (he/him) 🇬🇺 at #ASCO23 on how far we've come in treating patients with cancer over the past 20 years.

Visit our collection of ACS Statistics to learn more about the progress being made:
acsjournals.onlinelibrary.wiley.com/doi/toc/10.332…

As it will clearly remain an issue at #GI24 and beyond I'm remembering Anirban Maitra's admonition at #ASCO23 that calculating PDL1 CPS scores is not as exact a science as we might like for a metric on which we are predicating major therapeutic choices for our patients

Quick break from Cedars-Sinai Genitourinary Oncology Retreat to reflect on #ASTRO23 and thank ASTRO Chair Jeff Michalski for an incredibly Family-Friendly annual meeting!

Our daughters loved their “Future ASTRO Member” badges to match their #ASCO23 ones!

Cancer at Cedars-Sinai Cedars-SinaiMed

At ASCO23, initial dose-finding results were released for TORL-1-23, an anti-CLDN6 ADC based on familiar chemistry and MMAE. TORL emphasized its superior safety and tolerability profile compared to existing MMAE-ADCs, citing the relatively 'low systemic exposure' to the free

ICYMI: At #ASCO23 , PhRMA’s Chief Medical Officer Dr. Mike spoke of some of the exciting developments that were shared. This progress was made possible by a policy environment that supports access and innovation. Read more: onphr.ma/3NvsKQp

Access to childcare & transportation significantly impact a person’s ability to access cancer treatment. At our #ASCO23 Patient Forum, swaggsheila shared how empathy & partnering w/ patients during treatment can help overcome barriers: brnw.ch/21wEyTe #ASCOHealthEquity